WST · Q1 2026 Earnings

Bullish

West Pharmaceutical Services

Reported April 23, 2026

30-second summary

Q1 revenue of $844.9M (+21% reported / +15.3% organic) blew past the $770–790M guide by ~$55–75M, with adjusted EPS of $2.13 crushing the $1.65–1.70 range by $0.43–0.48 (25–29% upside). Management responded by raising FY2026 revenue guidance by $77.5M at the midpoint to $3.295–3.350B and adjusted EPS by $0.55 to $8.40–8.75 (+6.8% midpoint), lifting FY organic growth to 7–9% from 5–7%. This is the fourth consecutive guide-raise quarter, and the "very conservative start" language from Q4 has been validated in a single print rather than back-loaded.

Headline numbers

EPS

Q1 FY2026

$2.13

Revenue

Q1 FY2026

$0.84B

+21.0% YoY

Gross margin

Q1 FY2026

35.1%

Free cash flow

Q1 FY2026

$0.05B

Operating margin

Q1 FY2026

21.0%

Key financials

Q1 FY2026

Metric	Q1 FY2026	YoY	Q4 FY2025	QoQ
Revenue	$0.84B	+21.0%	$0.81B	+5.0%
EPS	$2.13	—	$2.04	+4.4%
Gross margin	35.1%	—	37.8%	-270bps
Operating margin	21.0%	—	19.5%	+150bps
Free cash flow	$0.05B	—	—	—

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Revenue	Q1 FY2026	$770M to $790M	$844.9M	+$54.9M to $74.9M above guide	Beat
Adjusted-Diluted EPS	Q1 FY2026	$1.65 to $1.70	$2.13	+$0.43 to $0.48 above guide	Beat
Organic Revenue Growth	Q1 FY2026	4.6% to 7.4%	15.3%	+7.9 to 10.7 percentage points above guide	Beat
Reported Revenue Growth	Q1 FY2026	10.3% to 13.2%	21.0%	+7.8 to 10.7 percentage points above guide	Beat

New guidance

Metric	Period	Guide	YoY
Revenue	Q2 FY2026	$830M to $850M	+7.8 to +10.4%
Reported Revenue Growth	Q2 FY2026	8.3% to 10.9%	—
Organic Revenue Growth	Q2 FY2026	7.0% to 9.6%	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY2026	$3.215B to $3.275B	$3.295B to $3.350B	+$80M to $75M at midpoint	Raised
Adjusted-Diluted EPS	FY2026	$7.85 to $8.20	$8.40 to $8.75	+$0.55 to $0.55; midpoint +$0.55 (6.8%)	Raised
Reported Revenue Growth	FY2026	4.6% to 6.5%	7.2% to 9.0%	+2.6 to +2.5 percentage points	Raised
Organic Revenue Growth	FY2026	5% to 7%	7% to 9%	+2.0 to +2.0 percentage points	Raised

Reaffirmed unchanged this quarter: Capital Expenditures ($250M to $275M)

Segment KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
HVP Components	$0.409B	+29.6%
Standard Products	$0.161B	+6.7%
HVP Delivery Devices	$0.124B	+29.0%
West Vantage	$0.151B	+11.6%
Biologics	$0.355B	+31.6%
HVP Components organic growth	22.6%	—
HVP Delivery Devices organic growth	27.5%	—
Biologics organic growth	25.9%	—

Other KPIs

Q1 FY2026

Segment	Q1 FY2026	YoY
Americas	$0.377B	+11.3%
Europe, Middle East, Africa	$0.399B	+30.1%
Asia Pacific	$0.068B	+30.7%
Organic revenue growth	15.3%	—
Operating margin	21.0%	—
Adjusted operating margin	21.4%	—
Operating cash flow	$89.9M	—
Share repurchases	$297.6M (1.2M shares)	—

Management tone

Q2 FY2025 → Q3 FY2025 → Q4 FY2025 → Q1 FY2026: "Transition year retired" → "Destocking behind us" → "Conservative start to 2026" → "Demand outpacing supply, full-year raised after one quarter."

The "conservative start" framing from Q4 was validated in a single quarter rather than back-loaded. Three months ago management explicitly told investors the FY2026 guide was conservative and the 10% GLP-1 growth assumption was understated. Q1 organic growth of 15.3% against a 4.6–7.4% guide — more than double the high end — and a $0.55 EPS midpoint raise after just one quarter is the cleanest possible vindication of that framing. The pattern is now mechanical: West sets guidance with embedded conservatism, then raises after Q1.

The Annex 1 contribution was extended from European tailwind to multi-year, global structural driver. In Q3 FY2025 management lifted the 2025 Annex 1 contribution from 150bps to 200bps. This quarter, in Q&A, the framing became: 6+ billion units identified as conversion targets, 200bps annual contribution sustained across "multiple years," and explicit expansion of the regulatory environment "beyond Europe… particularly around contamination." APAC at +30.7% in Q1 is the first quantitative evidence that the tailwind is genuinely global rather than EU-concentrated.

The non-GLP-1 growth thesis is being explicitly demonstrated rather than asserted. Q4 reframed non-GLP-1 HVP Components as "four of five points of growth" — a forward claim. Q1 produced HVP Components organic growth of 22.6% with non-GLP-1 specifically growing "high teens" (per Q&A) and biologics +26%. Management is no longer defending diversification away from GLP-1 dependency; the print does the defending.

Margin commentary signaled H2 acceleration without retreating on the Q1 result. Adjusted operating margin of 21.4% with 350bps YoY expansion is already meaningfully above the ">100bps for the year" FY guide. In Q&A management said H2 operating margins would be "materially better than first half" — meaning the >100bps full-year target now looks like a floor, not a target. The labor-ramp explanation for sequential softness (March stronger than January) reads as a deliberate set-up for further raises.

Demand-quality concerns were addressed head-on and dismissed. Asked specifically about Middle East conflict pull-forward, management stated they had analyzed the order book and found none, attributing SmartDose 3.5mL outperformance to transaction-timing (the AbbVie sale) rather than external events. The willingness to confirm "no pull-forward" definitively — rather than hedging — matches the broader posture of treating contested points as closed.

Q&A highlights

Patrick Donnelly · Citi

Asked about acceleration in non-GLP-1 HVP components revenue growth (noted at low double digits for rest of year). Sought breakdown between NX1, biosimilars, and biologics drivers.

Management attributed growth primarily to strong demand in biologics and biosimilars (26% growth in Q1), with most growth from already-commercialized drugs rather than new launches. Annex 1 projects up 66% year-over-year. Emphasized operational excellence at European manufacturing sites enabling capacity increases to meet rising demand.

Non-GLP-1 HVP components grew in high teens in Q1Biologics grew 26% organically in Q1Annex 1 projects up 66% year-over-yearNon-GLP-1 expected to grow low double digits for full year

Callum Titchmarch · Morgan Stanley

Followed up on Annex 1 durability, customer adoption challenges, and realistic TAM capture. Also asked about APAC demand environment showing 29% growth in Q1.

Management stated Annex 1 is early innings with 6+ billion units targeted for conversion, representing multi-year tailwind. Regulatory environment expanding globally beyond Europe. APAC growth driven by biologics/biosimilars participation and local CDMOs/biotech firms expanding into Western markets. Strong customer execution in region leveraging higher-end HVP portfolio.

6 billion+ units identified as targets for Annex 1 conversion200 basis points annual growth contribution from Annex 1 for multiple years expectedAPAC grew 29% in Q1Regulatory environment expanding across globe, particularly around contamination

Michael Riskin · Bank of America

Asked whether Middle East conflict caused unusual ordering patterns, customer pre-buying, or stocking in anticipation of oil price increases or supply constraints.

Management explicitly stated they conducted analysis and found no pull-forward ordering associated with Middle East conflict. Confirmed SmartDOS 3.5 revenue outperformance was transaction-related, not conflict-driven. Discussed multiple mitigation tools for cost offsets including hedging, similar to tariff mitigation approach, though premature to detail all strategies.

No pull-forward ordering from Middle East conflict identifiedSmartDOS 3.5 outperformance driven by transaction anticipation, not external eventsCompany has hedging programs in place for commodity costsMultiple mitigation tools available similar to tariff offset strategies

Justin Bowers · Deutsche Bank

Asked for update on manufacturing capacity in Dublin and West Coast, and GLP-1 market expansion to other indications beyond diabetes and obesity.

Management indicated Dublin facility will transition from CGM to drug handling and new customer launches by end of H2 2026. Drug handling aligned with West Vantage strategy and non-GLP-1 drug handling area. Multiple GLP-1 pipeline projects for other indications ongoing; combination molecules and other biologic types being developed. Strong market position in pipeline.

CGM contract finishes end of Q2 2026Dublin facility transitioning to drug handling and new commercial launches in H2 2026Drug handling business is higher margin, less capital intensive than legacy contract manufacturingMultiple GLP-1 projects in pipeline for other indications

David Windley · Jefferies

Asked about incremental margin opportunity despite strong year-over-year expansion but sequential margin decline. Sought clarification on labor ramp, commodity burden, and SmartDOS volume impact on margins.

Management attributed sequential softness to labor ramp-up occurring throughout quarter (March stronger than January) and SmartDOS volume mix impact. Highlighted HPP components margin expansion drivers: biologics growth, NovaPeer strength, Annex 1 conversion, and operational excellence. Expects incremental margins to improve as year progresses, with second half materially better than first half on operating margin basis.

Q1 margin 21.4% (350 basis points YoY expansion)Labor ramp continued through quarter with improving cadenceSmartDOS had margin headwind in Q1Second half expected to have much higher operating margins than first half

Answers to last quarter's watch list

Q1 FY2026 organic growth landing inside the 4.6%–7.4% guide. Organic growth of 15.3% printed more than 2x the high end. The "very conservative start" framing was understatement — non-GLP-1 HVP Components alone drove the beat, with biologics +26% and HVP Components organic +22.6%. Status: Resolved positively

HVP Components organic growth holding ≥10% in Q1. HVP Components organic growth of 22.6% blew through the threshold. The "four of five points of total growth" trajectory is running ahead of schedule from Q1, not back-half-weighted. Status: Resolved positively

Operating margin expansion pace through H1. Adjusted operating margin of 21.4% expanded 350bps YoY in Q1 alone — well above the >100bps FY framing. Management guided H2 "materially better than first half," meaning the full-year target now looks like a floor. Status: Resolved positively

HVP Delivery Devices ex-SmartDose run-rate. Management did not provide a clean ex-SmartDose disclosure; HVP Delivery Devices printed +29% reported / +27.5% organic, but Q&A confirmed SmartDose 3.5mL transaction timing contributed to the result. SmartDose 3.5mL revenue of $55M in H2 2025 is being excluded from the FY2026 organic growth calc, but a residual delivery-device base wasn't broken out. Status: Continue monitoring

GLP-1 dollar disclosure update. No fresh GLP-1 revenue mix disclosure this quarter beyond Q&A commentary that non-GLP-1 HVP Components drove the outperformance and grew "high teens." The prior 17% combined GLP-1 disclosure was not refreshed. Status: Continue monitoring

Tariff impact reconciliation into FY2026. Management confirmed in Q&A that mitigation tools (hedging, similar to tariff offset playbook) are addressing rising oil and commodity costs, with single-digit-millions net impact expected. No incremental tariff drag flagged. Status: Resolved positively

What to watch into next quarter

Q2 FY2026 organic growth landing in the upper half of the 7.0%–9.6% guide. The pattern of conservative guides being beat by 700+bps is now established — a Q2 print at or below the midpoint would suggest Q1 captured an unusual amount of demand pull-forward (despite management's denial), while a print above 10% would confirm the FY2026 raise is itself still conservative.

HVP Components organic growth holding ≥15% in Q2. A deceleration toward "low double digits" (the FY framing) would be normalization; sustained 20%+ would force another FY raise.

First clean disclosure of HVP Delivery Devices ex-SmartDose run-rate. With the AbbVie close assumed mid-year, the Q2 print should be the last quarter with SmartDose 3.5mL in the base — watch for explicit pro-forma framing.

Adjusted operating margin holding above 21% sequentially. Q1's 21.4% sets a high bar; management's "H2 materially better" framing implies Q2 should at minimum match, with Q3/Q4 stepping up. Sequential compression below 21% would undermine the FY margin trajectory.

Any quantification of FY2026 GLP-1 revenue mix update. The 17% combined GLP-1 disclosure is now two quarters stale; a refresh would frame how much of the FY raise is GLP-1 driven versus diversified.

Capex cadence relative to the unchanged $250–275M FY range. With operating margins expanding and FCF needing to inflect, watch for any signal that capex is tracking below the range — which would accelerate the FCF normalization toward the 6–8% of sales corridor.

Sources

West Pharmaceutical Services Q1 2026 Earnings Release (SEC EDGAR): https://www.sec.gov/Archives/edgar/data/105770/000010577026000047/exh991q12026earningsrelease.htm
West Pharmaceutical Services Q1 2026 conference call Q&A (referenced for non-GLP-1 HVP growth, Annex 1 TAM, APAC drivers, Middle East demand quality, Dublin transition, margin cadence)
Tapebrief Q4 2025, Q3 2025, Q2 2025 WST briefs (referenced for prior-quarter guidance trajectory, watch list, and tone arc)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.